VANQUA BIO, INC.
CHICAGO, IL · Founded 2019 · CIK 0001790072 · Biotech · Private
Therapeutic molecules for neurodegenerative disease treatment
vanquabio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $136M
- 3 Form D · Jul 2024
- 27 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 20
- 0 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,000,000 | |
| Private capital raised | Form D · SEC | $84,999,987 | |
| Private capital raised | Form D · SEC | $44,979,987 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2799 | Black Diamond Therapeutics | — | $140M |
| 2800 | VYNE Therapeutics Inc. | — | $139M |
| 2801 | Silverback Therapeutics | — | $139M |
| 2802 | VANQUA BIO, INC. | — | $136M |
| 2803 | Chroma Medicine | — | $135M |
| 2804 | ANSA BIOTECHNOLOGIES, INC. | — | $123M |
| 2805 | Frontier Medicines | — | $122M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Mona AshiyaDirector
- MONA ASHIYADirector
- Uya ChuluunbaatarDirector
- Bernard DavitianDirector
- Viola MeehanExecutive Officer
- Sara NayeemDirector
- Jonathan SilversteinDirector
- JONATHAN SILVERSTEINDirector · Executive Officer
- Stephen SquintoDirector
- James SullivanDirector · Executive Officer
- JAMES SULLIVANDirector · Executive Officer
- Rand SutherlandDirector
Patents
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Oligonucleotides For Targeting Complement C5application
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Oligonucleotides For Targeting Complement C5application
- C5AR1 Antagonists And Uses Thereofapplication
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
- Small Molecule Modulators Of Glucocerebrosidase Activity And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.